Sign inJoin waitlistJoin the waitlist

Ran Reshef

Director of Translational Research, Blood and Marrow Transplantation Program · Columbia University

Credentials: · · · ·

History

Blood and Marrow Transplantation Program · Columbia University
2015–Present
Cell Therapy Program · Columbia University
Present
CUMC
Present

Perelman School of Medicine University of Pennsylvania
Until 2009
Tel Aviv Sourasky Medical Center
Until 2007
Sackler School of Medicine, Tel Aviv University
2003
Tel Aviv Sourasky Medical Center
Until 1998

Research

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Biology of Blood and Marrow Transplantation · 2016 · 880 citations
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
The Lancet Oncology · 2022 · 573 citations
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
New England Journal of Medicine · 2023 · 550 citations

Elizabeth Hexner
38 papers
David Porter
28 papers
John Levine
27 papers
William Hogan
27 papers
Muna Qayed
24 papers
James Ferrara
23 papers
Carrie Kitko
22 papers
Ryotaro Nakamura
21 papers
Aaron Etra
20 papers
Alison Loren
19 papers
Zachariah DeFilipp
18 papers
Edward Stadtmauer
17 papers

Grants

Neuropeptide Y Receptor Signaling in Gut GVHD: Targeting Y1/Y2 Pathways for Immune Modulation
National Cancer Institute · R03
Contact PI · $164.5K · Columbia University Health Sciences
2026–2028
Effector T-Cell Trafficking in Graft-Versus-Host Disease
National Heart, Lung, and Blood Institute · R01
Contact PI · $2M · Columbia University Health Sciences
2019–2024
Lymphocyte Trafficking Blockade in Allogeneic Stem-Cell Transplantation
National Cancer Institute · K23
Contact PI · $520.3K · Columbia University Health Sciences
2013–2017

Clinical trials

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Site PI · Recruiting · Phase 3
TScan Therapeutics, Inc.
2026–2029
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Site PI · Recruiting · Phase 1
Vittoria Biotherapeutics
2024–2029
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 1
Imugene Limited
2019–2027